Imiprmaine vs. Sertraline in Panic Disorder: 24-Week Treatment Completers

Annals of Clinical Psychiatry

Volumn 15, Issue 3-4, 2003, Pages 171-180

  Mavissakalian, Matig R ^a,b,c  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b LOUIS STOKES CLEVELAND VA MEDICAL CENTER   (United States)

^c UNIVERSITY HOSPITALS OF CLEVELAND   (United States)

Author keywords

Imipramine; Panic disorder; Sertraline; Treatment completers

Indexed keywords

IMIPRAMINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ACCOMMODATION; ADULT; ARTICLE; ATAXIA; BODY WEIGHT; CARDIOVASCULAR DISEASE; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DROWSINESS; DRUG EFFICACY; FEMALE; HEADACHE; HEART RATE; HUMAN; LONG TERM CARE; MALE; MICTURITION DISORDER; NAUSEA; NEUTROPENIA; PANIC; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEXUAL DYSFUNCTION; SIDE EFFECT; SINGLE BLIND PROCEDURE; SWEATING; TACHYCARDIA; TREATMENT OUTCOME; TREMOR; VERTIGO; VISUAL IMPAIRMENT; VOMITING; WEIGHT GAIN; XEROSTOMIA;

ADULT; AGORAPHOBIA; ANTIDEPRESSIVE AGENTS, TRICYCLIC; COHORT STUDIES; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMIPRAMINE; LONG-TERM CARE; MALE; MIDDLE AGED; PANIC DISORDER; PERSONALITY ASSESSMENT; RECURRENCE; SEROTONIN UPTAKE INHIBITORS; SERTRALINE; TREATMENT OUTCOME;

EID: 0842327254     PISSN: 10401237     EISSN: None     Source Type: Journal    
DOI: 10.1023/B:ACLI.0000008170.74985.b6     Document Type: Article

References (20)

1. Lecrubier Y, Bakker A, Dunbar G, Judge R, Collaborative Paroxetine Panic Study Investigators: A comparison of paroxetine, clomipramine, and placebo in the treatment of panic disorder. Acta Psychiatry Scand 1997; 95:145-152
2. Wade AG, Lepola U, Koponen HJ, Pedersen V, Pedersen T: The effects of citalopram in panic disorder. Br J Psychiatry 1997; 170:549-553
3. Bakish D, Hooper CL, Fiteau MJ, Charbonneau Y, Fraser G, Dixy LW, Thibaudeau C, Raine D: A double-blind placebo-controlled trial comparing fluvoxamine and imipramine in the treatment of panic disorder with our without agoraphobia. Psychopharmacol Bull 1996; 32:135-141
4. Sheehan DV, Lecrubier Y, Harnett-Sheehan K, Janavs J, Weiller E, Keskiner A, Schinka J, Knapp E, Sheehan MF, Dunbar GC: Reliability and validity of the MINI international neuropsychiatric interview (M.I.N.I): according to the SCID-P. Eur Psychiatry 1997; 12:232-241
5. Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 1960; 23:56-62
6. Mavissakalian MR, Perel JM: Imipramine in panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 1995; 152:673-682
7. Londborg PD, Wolkow R, Smith WT, et al.: Sertraline in the treatment of panic disorder. Br J Psychiatry 1998; 173:54-60
8. Mavissakalian MR, Perel JM, Talbott-Green M, Sloan C: Gauging the effectiveness of extended imipramine treatment for panic disorder with agoraphobia. Biol Psychiatry 1998; 43:848-854
9. Mavissakalian MR, Perel JM: Long-term maintenance and discontinuation of imipramine therapy in panic disorder with agoraphobia. Arch Gen Psychiatry 1999; 56:821-827
10. Mavissakalian MR, Perel JM, deGroot C: Imipramine treatment of panic disorder with agoraphobia: The second time around. J Psychiatry Res 1993; 27:61-68
11. Marks IM, Matthews AM: Brief standard self-rating for phobic patients. Behav Res Ther 1979; 17:263-267
12. Beck AT, War CH, Medelson M, Mock J, Erbaugh J: An inventory for measuring depression. Arch Gen Psychiatry 1961; 4:53-64
13. Peterson RA, Reiss S: Anxiety Sensitivity Index Revised Test Manual. Worthington, OH: International Diagnostics Services; 1992
14. Montgomery SA: Selective norepinephrine reuptake inhibion: The unique role of reboxetine in depression, pp 688-691. In: Nelson JC, chair. Novel Antidepressant Strategies to Optimize Outcome (Academic Highlights). J Clin Psychiatry 2000; 61:686-696
15. Versiani M, Cassana G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 2002; 63:31-37
16. Mavissakalian MR, Perel JM: The side effects burden of extended imipramine treatment of panic disorder. J Clin Psychopharmacol 2002; 20:547-555
17. Mavissakalian M, Perel J, Guo S: Specific side effects of long-term imipramine management of panic disorder. Clin Psychopharmacol 2002; 22:155-161
18. Piazza LA, Markowitz JC, Kocsis JH, Leon AC, Portera L, Miller NL, Adler D: Sexual function in chronically depressed patients treated with SSRI antidepressants: A pilot study. Am J Psychiatry 1997; 154:1757-1759
19. Labbate LA, Grimes JB, Arana GW: Serotonin reuptake antidepressant effects on sexual function in patients with anxiety disorders. Biol Psychiatry 1998; 43:904-907
20. Ware MR, Emmanuel NP, Johnson MR, Brawman-Mintzer O, Knapp R, Crawford-Harrison M, Lydiard RB: Self-reported sexual dysfunctions in anxiety disorder patients. Psychopharmcol Bull 1996; 32:530